Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11706017
Kwon YW, et al. (2002) Mechanism of p53-dependent apoptosis induced by 3-methylcholanthrene: involvement of p53 phosphorylation and p38 MAPK. J Biol Chem 277, 1837-44 11706017
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T71-p - ATF-2 (human)
Modsite: IVADQtPtPtRFLkN SwissProt Entrez-Gene
Orthologous residues
ATF‑2 (human): T71‑p, ATF‑2 (mouse): T53‑p, ATF‑2 (rat): T53‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methylcholanthrene increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methylcholanthrene increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methylcholanthrene increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methylcholanthrene increase

S15-p - p53 (human)
Modsite: PsVEPPLsQEtFsDL SwissProt Entrez-Gene
Orthologous residues
p53 (human): S15‑p, p53 iso2 (human): S15‑p, p53 iso4 (human): , p53 (mouse): S18‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (green monkey): S15‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, liver cancer
Relevant cell lines - cell types - tissues:  HepG2 (hepatic), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methylcholanthrene increase
naphthoflavone methylcholanthrene inhibit treatment-induced increase
SB203580 methylcholanthrene inhibit treatment-induced increase
wortmannin methylcholanthrene inhibit treatment-induced increase
etoposide increase
wortmannin etoposide inhibit treatment-induced increase